As aforementioned, the elimination of MDSCs in the TME by inhibiting the IL-1 pathway is a potential strategy to overcame tumor resistance to immunotherapies such as immune checkpoint blockades [381],which has been evaluated in different models. This evidence concerns the gene IL1B and neoplasm.